LLY ▲ +0.9% - Eli Lilly and Company $LLY - FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly shares rose 0.9% following FDA approval of Mounjaro (tirzepatide) for reducing cardiovascular risk in adults with type 2 diabetes. The expanded indication broadens the drug's therapeutic use beyond its original weight-loss and glucose-control applications, potentially opening a larger patient population and additional revenue opportunities for the company's blockbuster treatment. 28-AUG-2026 07:00 AM ET